Printer Friendly

REALITY FEMALE CONDOM DEVELOPER RECEIVES ENTREPRENEUR AWARD

 REALITY FEMALE CONDOM DEVELOPER RECEIVES ENTREPRENEUR AWARD
 JACKSON, Wis., Sept. 17 /PRNewswire/ -- John A. Wundrock, R.Ph., president and CEO of Wisconsin Pharmacal Co. Inc. (WPC) (NASDAQ: WPCI) announced today that Mary Ann Leeper, Ph.D., senior vice-president, development, is the recipient of the 1992 Entrepreneurial Woman of the Year Award from the Women's Business Development Center in Chicago. The award recognizes Dr. Leeper's achievements. In particular, the award highlights her contribution in the development of the REALITY female condom and the important role the female condom will play for all women in preventing the spread of AIDS, other sexually transmitted diseases and unintended pregnancy.
 Today, over 70 percent of new HIV infections are from heterosexual intercourse. It is projected by the year 2000 the most of the people with new infections of HIV will be women. Once approved, REALITY will be the first new product to help prevent AIDS since the epidemic began more than a decade ago.
 Wisconsin Pharmacal initiated development of the female condom five years ago. Although a small company with limited resources, WPC recognized the potential contribution to public health that this new, innovative product could make and elected to invest in its development. A Premarket Approval Application (PMA) was submitted to U.S. Food and Drug Administration (FDA) in October 1991. In January 1992, an FDA Advisory Panel unanimously recommended approval contingent on the completion of certain studies and provision of additional information. WPC submitted the study results and required information to FDA in July 1992.
 While the average time for FDA review of PMA's is greater than two years, in view of the potential contribution of such a product, FDA has put the review of REALITY on a fast-track time schedule.
 -0- 9/17/92
 /CONTACT: John A. Wundrock, president and CEO, 414-677-4121 or Dr. Mary Ann Leeper, senior vice-president, research and development, 312-280-8541, both for Wisconsin Pharmacal Co./
 (WPCI) CO: Wisconsin Pharmacal Co. Inc. ST: Wisconsin IN: MTC SU:


PS -- NY008 -- 0442 09/17/92 08:27 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1992
Words:336
Previous Article:APPLE USA SET TO LAUNCH THE APPLE CATALOG; FIRST MAILING MID-OCTOBER TO OVER 1 MILLION CUSTOMERS
Next Article:TWO VOLKSWAGEN MODELS TOP SAFETY STUDY BY HIGHWAY LOSS DATA INSTITUTE
Topics:


Related Articles
REALITY FEMALE CONDOM APPROVED BY FDA
REALITY(R) FEMALE CONDOM FIRST U.S. SHIPMENTS
LONDON FACILITY RECEIVES FDA NOD; FEMALE CONDOM TO BEGIN APPEARING IN U.S. STORES THIS SUMMER
FIRST SHIPMENTS OF FEMALE CONDOM ARRIVE IN U.S.; Public Sector Receives First Product from U.K. Facility
WISCONSIN PHARMACAL ESTABLISHES FEMALE HEALTH DIVISION FLAGSHIP PRODUCT IS REALITY FEMALE CONDOM
WISCONSIN PHARMACAL'S FEMALE HEALTH DIVISION BEGINS BUILDING SALES AND DISTRIBUTION NETWORK; VICE PRESIDENT, SALES JOINS COMPANY
FEMALE CONDOM LISTED FOR MEDICAID REIMBURSEMENT
REALITY FEMALE CONDOM MARKETING PROGRAM UNVEILED
STUDY FINDING: TWO-THIRDS OF WOMEN IN NEW YORK CITY STUDY LIKE REALITY FEMALE CONDOM
FEMALE CONDOM'S PRODUCT LABELING REVISED; SHELF LIFE EXTENDED

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters